Manuela Neumann

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. pmc Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies
    Manuela Neumann
    Institute of Neuropathology, University Hospital of Zurich, Schmelzbergstr 12, 8091 Zurich, Switzerland
    Acta Neuropathol 117:137-49. 2009
  2. pmc Molecular neuropathology of TDP-43 proteinopathies
    Manuela Neumann
    Institute of Neuropathology, University Hospital of Zurich, Switzerland
    Int J Mol Sci 10:232-46. 2009
  3. pmc FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations
    Manuela Neumann
    Institute of Neuropathology, Schmelzbergstr 12, 8091 Zurich, Switzerland
    Brain 134:2595-609. 2011
  4. pmc A new subtype of frontotemporal lobar degeneration with FUS pathology
    Manuela Neumann
    Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland
    Brain 132:2922-31. 2009
  5. doi Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations
    Manuela Neumann
    Institute of Neuropathology, University Hospital Zurich, Switzerland
    Acta Neuropathol 124:705-16. 2012
  6. pmc Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease
    Manuela Neumann
    Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland
    Acta Neuropathol 118:605-16. 2009
  7. doi The molecular basis of frontotemporal dementia
    Manuela Neumann
    Institute of Neuropathology, University Hospital of Zurich, Switzerland
    Expert Rev Mol Med 11:e23. 2009

Detail Information

Publications7

  1. pmc Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies
    Manuela Neumann
    Institute of Neuropathology, University Hospital of Zurich, Schmelzbergstr 12, 8091 Zurich, Switzerland
    Acta Neuropathol 117:137-49. 2009
    ....
  2. pmc Molecular neuropathology of TDP-43 proteinopathies
    Manuela Neumann
    Institute of Neuropathology, University Hospital of Zurich, Switzerland
    Int J Mol Sci 10:232-46. 2009
    ..This review summarizes the recent advances in our understanding on the molecular neuropathology and pathobiology of TDP-43 in FTLD and ALS...
  3. pmc FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations
    Manuela Neumann
    Institute of Neuropathology, Schmelzbergstr 12, 8091 Zurich, Switzerland
    Brain 134:2595-609. 2011
    ....
  4. pmc A new subtype of frontotemporal lobar degeneration with FUS pathology
    Manuela Neumann
    Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland
    Brain 132:2922-31. 2009
    ..These findings suggest that FUS is the pathological protein in a significant subgroup of sporadic FTD and reinforce the concept that FTD and amyotrophic lateral sclerosis are closely related conditions...
  5. doi Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations
    Manuela Neumann
    Institute of Neuropathology, University Hospital Zurich, Switzerland
    Acta Neuropathol 124:705-16. 2012
    ..Moreover, the absence of Trn1 in ALS-FUS provides further evidence that ALS-FUS and FTLD-FUS have different underlying pathomechanisms...
  6. pmc Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease
    Manuela Neumann
    Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland
    Acta Neuropathol 118:605-16. 2009
    ..No mutation in the FUS gene was identified in a single case with DNA available. These findings suggest that FUS may play an important role in the pathogenesis of NIFID...
  7. doi The molecular basis of frontotemporal dementia
    Manuela Neumann
    Institute of Neuropathology, University Hospital of Zurich, Switzerland
    Expert Rev Mol Med 11:e23. 2009
    ..This review will focus on the current understanding of the molecular basis of each of the major FTLD subtypes. It is anticipated that this knowledge will provide the basis of future advances in the diagnosis and treatment of FTD...